Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Starting treatment news

Show

From To
Immediate HIV Treatment Has Little Impact on Risk of Future Drug Resistance

Starting antiretroviral therapy (ART) immediately rather waiting until a person's CD4 count falls below 500 cells/µL has almost no impact on the person's risk of developing antiretroviral resistance over the next seven years, according to a study published online in the journal AIDS. In this 51,000-person analysis, the impact of immediate ART on acquired drug resistance disappeared almost completely among people starting treatment in 2005 or later.

Published
07 January 2018
From
The Body Pro
Dolutegravir and lamivudine potent and safe in people starting HIV therapy for the first time

The two-drug antiretroviral combination dolutegravir and lamivudine is virologically effective and safe in people starting HIV therapy for the first time, according to US research published in the

Published
28 December 2017
By
Michael Carter
NHS England have announced funding for immediate antiretroviral treatment for HIV patients

NHS England has announced that it has agreed that HIV antiretroviral medication will be provided to patients immediately once someone is diagnosed.

Published
19 December 2017
From
Gay Times
Baseline CD4 count biggest factor in long-term immune system improvements after starting HIV therapy

Pre-treatment CD4 cell count is the most important factor in immune recovery following the initiation of combination antiretroviral therapy (cART), according to the results of a large observational

Published
14 December 2017
By
Michael Carter
HIV drug resistance now high enough to trigger a change in first-line treatment in eastern and southern Africa

HIV drug resistance is increasing rapidly in southern and eastern Africa and Latin America and, as a result, it may soon be necessary to change the

Published
04 December 2017
By
Keith Alcorn
HIV diagnoses in English gay men have been falling since 2014

A new analysis by Public Health England of testing rates and HIV diagnoses from all of England’s sexual health clinics shows that the decline in

Published
08 November 2017
By
Gus Cairns
Starting ART immediately after HIV diagnosis cuts mortality risk by two-thirds for people with high CD4 cell counts

People with a high CD4 cell count who start antiretroviral therapy (ART) immediately after diagnosis with HIV cut their 12-month mortality risk by two-thirds, according

Published
06 November 2017
By
Michael Carter
Symtuza as effective as multi-pill combination in previously untreated people with HIV

The single-pill combination of darunavir, cobicistat, tenofovir alafenamide and emtricitabine (Symtuza) is just as effective as a multi-pill combination of darunavir, cobicistat, emtricitabine and the older formulation of

Published
28 October 2017
By
Keith Alcorn
New EACS treatment guidelines

Everyone with HIV and hepatitis C virus (HCV) co-infection should receive direct-acting antiviral treatment for hepatitis C and should receive the same treatment for hepatitis C as

Published
26 October 2017
By
Keith Alcorn
Symtuza protease inhibitor regimen maintains viral suppression for a year

People who switched from a multi-pill antiretroviral regimen to the first one-pill, once-daily regimen that includes a protease inhibitor maintained undetectable viral load for a year, according to

Published
13 October 2017
By
Liz Highleyman
← First12345...77Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.